Stephan Grupp Md Phd
Clinical trials sponsored by Stephan Grupp Md Phd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New CAR T-Cell therapy shows promise for kids with tough leukemia Results expected Sep 2027 (estimated)
-
Engineered immune cells take on tough T-Cell cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called BEAM-201 for children and young adults with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments. BEAM-201 uses donor-derived immune cells that are engin…
Phase 1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy takes on tough childhood leukemia
Disease control Recruiting nowThis early-phase trial is testing a new treatment called CART123 for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. CART123 cells are specially engineered immune cells designed to find and kill leukemia cells. …
Phase 1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New CAR T-Cell therapy shows promise for kids with tough leukemia
Disease control Recruiting nowThis study is testing a new version of CAR T-cell therapy for children with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to standard treatments. The therapy uses the patient's own immune cells, modified to target cancer cells. The trial aims to …
Phase 1/2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Double-Barreled CAR t attack shows promise for tough childhood leukemia
Disease control Recruiting nowThis study tests a new approach for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or not responded to treatment. It combines two types of engineered immune cells (CAR T cells) that target different markers on cancer cells (CD19 and …
Phase 1/2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Engineered immune cells take on childhood leukemia in new trial
Disease control Recruiting nowThis phase 2 trial is testing a personalized cell therapy called CART19 in children and young adults with certain high-risk forms of B-cell acute lymphoblastic leukemia (B-ALL). The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack c…
Phase 2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Immune reset: stem cell trial offers hope for teens with deadly autoimmune diseases
Disease control Recruiting nowThis study tests whether a stem cell transplant using the patient's own cells can help young people (ages 8 to 25) with life-threatening lupus or scleroderma. The goal is to wipe out the faulty immune system and allow a new, healthy one to grow. The trial will track how long pati…
Phase 2 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC